Abstract
In a metazoan body all cells possess the same set of genes. Exceptions for this condition are post-meiotic germ cell lines, mature lymphocytes, and cells in species that exhibit chromosome diminution. Therefore, generating a pluripotent cell in vitro and directing its conversion into a specific differentiated cell fate, which means rewinding the internal clock of any mammalian cell to an embryonic state and then forwarding this high potential cells to diseased cells, represents a rational and ongoing approach in regenerative medicine. On the other hand, quality control and safety are the main concerns and there are several technical challenges in using human iPSCs in treatment of several irreparable human diseases. To minimize or eliminate genetic alterations in the derived iPSC line creation factor-free human iPSCs are necessary. Defining a disease-relevant phenotype needs in vitro and in vivo models. Moreover, to generate markers for differentiation and gene corrections, gene-targeting strategies are necessary. Besides, cell-type specific lineage reporters, lineage-tracking tools and tools to disrupt, repair, or overexpress genes should be developed in order to model many human diseases.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Apostolou E, Hochedlinger K (2011) Stem cells: iPS cells under attack. Nature 474(7350):165–166
Bryceson YT, Long EO (2008) Line of attack: NK cell specificity and integration of signals. Curr Opin Immunol 20(3):344–352
Colman A, Dreesen O (2009) Pluripotent stem cells and disease modeling. Cell Stem Cell 5(3):244–247
Daley GQ et al (2009) Broader implications of defining standards for the pluripotency of iPSCs. Cell Stem Cell 4(3):200–201; author reply 202
Ebert AD et al (2009) Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 457(7227):277–280
Garg V et al (2003) GATA4 mutations cause human congenital heart defects and reveal an interaction with TBX5. Nature 424(6947):443–447
Ghosh TK et al (2009) Physical interaction between TBX5 and MEF2C is required for early heart development. Mol Cell Biol 29(8):2205–2218
Hanna JH et al (2010) Pluripotency and cellular reprogramming: facts, hypotheses, unresolved issues. Cell 143(4):508–525
Hochedlinger K, Plath K (2009) Epigenetic reprogramming and induced pluripotency. Development 136(4):509–523
Ieda M et al (2010) Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell 142(3):375–386
Kim K et al (2010) Epigenetic memory in induced pluripotent stem cells. Nature 467(7313):285–290
Kloc M, Zagrodzinska B (2001) Chromatin elimination–an oddity or a common mechanism in differentiation and development? Differentiation 68(2–3):84–91
Kocaefe C et al (2010) Reprogramming of human umbilical cord stromal mesenchymal stem cells for myogenic differentiation and muscle repair. Stem Cell Rev 6(4):512–522
Lee G et al (2009) Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature 461(7262):402–406
Lin Q et al (1997) Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C. Science 276(5317):1404–1407
Masip M et al (2010) Reprogramming with defined factors: from induced pluripotency to induced transdifferentiation. Mol Hum Reprod 16(11):856–868
Mattis VB, Svendsen CN (2011) Induced pluripotent stem cells: a new revolution for clinical neurology? Lancet Neurol 10(4):383–394
Meissner A (2010) Epigenetic modifications in pluripotent and differentiated cells. Nat Biotechnol 28(10):1079–1088
Nakatsuji N (2010) Banking human pluripotent stem cell lines for clinical application? J Dent Res 89(8):757–758
Osafune K et al (2008) Marked differences in differentiation propensity among human embryonic stem cell lines. Nat Biotechnol 26(3):313–315
Raya A et al (2009) Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature 460(7251):53–59
Saha K, Jaenisch R (2009) Technical challenges in using human induced pluripotent stem cells to model disease. Cell Stem Cell 5(6):584–595
Swijnenburg RJ et al (2005) Embryonic stem cell immunogenicity increases upon differentiation after transplantation into ischemic myocardium. Circulation 112(9 Suppl):I166–I172
Tamaoki N et al (2010) Dental pulp cells for induced pluripotent stem cell banking. J Dent Res 89(8):773–778
Taylor CJ et al (2011) Immunological considerations for embryonic and induced pluripotent stem cell banking. Philos Trans R Soc Lond B Biol Sci 366(1575):2312–2322
Vierbuchen T et al (2010) Direct conversion of fibroblasts to functional neurons by defined factors. Nature 463(7284):1035–1041
Xie H et al (2004) Stepwise reprogramming of B cells into macrophages. Cell 117(5):663–676
Ye Z et al (2009) Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. Blood 114(27):5473–5480
Zhao T et al (2011) Immunogenicity of induced pluripotent stem cells. Nature 474(7350):212–215
Zhou Q et al (2008) In vivo reprogramming of adult pancreatic exocrine cells to beta-cells. Nature 455(7213):627–632
Zhu H et al (2011) Investigating monogenic and complex diseases with pluripotent stem cells. Nat Rev Genet 12(4):266–275
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2012 The Author(s)
About this chapter
Cite this chapter
Yildirim, S. (2012). Challenges to Therapeutic Potential of hiPSCs. In: Induced Pluripotent Stem Cells. SpringerBriefs in Stem Cells. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-2206-8_6
Download citation
DOI: https://doi.org/10.1007/978-1-4614-2206-8_6
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-2205-1
Online ISBN: 978-1-4614-2206-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)